Spark Therapeutics

UK cost watchdog recommends Novartis' blindness therapy Luxturna
UK cost watchdog recommends Novartis' blindness therapy Luxturna
Yahoo/Reuters
Novartis
gene therapy
Luxturna
UK
NICE
Spark Therapeutics
Flag link:
Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?
Roche stays mum about FTC, CMA reviews as $4.3B Spark deal faces yet another delay. What's up?
Endpoints
Roche
Spark Therapeutics
FTC
CMA
M&A
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
Yahoo/Benzinga
biotech
earnings
Immunic
Alkermes
Conatus
Aevi Genomic
Tricida
Curis
Ultragenyx
Leap Therapeutics
Cidara Therapeutics
Akcea
Spark Therapeutics
Eli Lilly
AnaptysBio
clinical trials
Flag link:
Roche, Spark push back takeover deadline in $4.3 billion deal
Roche, Spark push back takeover deadline in $4.3 billion deal
Yahoo/Reuters
Roche
Pharma CEOs
Severin Schwan
M&A
Spark Therapeutics
Flag link:
Sangamo backs up early success for hemophilia gene therapy
Sangamo backs up early success for hemophilia gene therapy
Biopharma Dive
Sangamo
gene therapy
hemophilia A
SB-525
Pfizer
Spark Therapeutics
Biomarin
Flag link:
The top 10 most-expensive meds in the U.S.—and they're not the usual suspects
The top 10 most-expensive meds in the U.S.—and they're not the usual suspects
Fierce Pharma
drug pricing
GoodRx
Novartis
Spark Therapeutics
Zolgensma
Luxturna
Flag link:
FTC demands could mean months-long delay for Roche-Spark deal
FTC demands could mean months-long delay for Roche-Spark deal
Biopharma Dive
Roche
Spark Therapeutics
FTC
M&A
Flag link:
Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout
Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout
Endpoints
Spark Therapeutics
Roche
FTC
UK
M&A
Flag link:
What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay
What's taking the FTC so long? Roche won't say, but insists it will bag Spark on time — despite third delay
Endpoints
Roche
Spark Therapeutics
M&A
Flag link:
Roche delays $4.3B Spark buyout — again — as FTC review drags on
Roche delays $4.3B Spark buyout — again — as FTC review drags on
Endpoints
Roche
Spark Therapeutics
M&A
FTC
Flag link:
Roche must ask Spark shareholders once again to sell
Roche must ask Spark shareholders once again to sell
Biopharma Dive
Roche
Spark Therapeutics
gene therapy
M&A
Flag link:
Gene therapy progress spurs competition in biotech buyouts
Gene therapy progress spurs competition in biotech buyouts
Biopharma Dive
biotech
gene therapy
M&A
Biogen
Nightstar Therapeutics
Roche
Spark Therapeutics
Flag link:
Spark bidding war drove Roche bid up by $2.1 billion
Spark bidding war drove Roche bid up by $2.1 billion
BioCentury
Spark Therapeutics
Roche
M&A
Flag link:
Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy
Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy
Xconomy
Roche
gene therapy
Spark Therapeutics
M&A
Flag link:
This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why
This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why
Investors Business Daily
uniQure
M&A
hemophilia B
AMT-061
Pfizer
Spark Therapeutics
Flag link:
Uniqure turns the screw on Spark and Pfizer
Uniqure turns the screw on Spark and Pfizer
EP Vantage
uniQure
Spark Therapeutics
Pfizer
AMT-061
hemophilia B
Flag link:
JPM19: Spark looks at scale, manufacturing as gene therapy matures
JPM19: Spark looks at scale, manufacturing as gene therapy matures
Biopharma Dive
JPMHC 2019
Spark Therapeutics
gene therapy
Luxturna
Flag link:
2 Sets of Disasters Biotech Will Pay For in 2019
2 Sets of Disasters Biotech Will Pay For in 2019
Yahoo/Motley Fool
Gilead Sciences
Yescarta
Novartis
Kymriah
Spark Therapeutics
Luxturna
Flag link:
Luxturna cleared for sale in Europe, but payer support uncertain
Luxturna cleared for sale in Europe, but payer support uncertain
Biopharma Dive
Spark Therapeutics
Luxturna
Europe
gene therapy
Flag link:
Novartis/Spark’s sight gene therapy approved in EU
Novartis/Spark’s sight gene therapy approved in EU
Pharmaforum
Novartis
Spark Therapeutics
Luxturna
gene therapy
Europe
Flag link:

Pages